CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 5 enrolled
Drug / intervention
Testosteronedrug
Likely dose
Testosterone 11 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02611154
NCT02611154Phase 4Completed
CompareCT.gov

Intranasal Delivery of Testosterone and Its Effect on Doping Markers

University of Utah·interventional·Posted Nov 20, 2015·Updated Feb 11, 2020

In Brief

A Phase 4 clinical trial evaluating Testosterone for Abuse of Anabolic Steroids. Completed, enrolled 5 participants across 1 site.

Detailed Summary

Hypothesis: Intranasal administration of exogenous testosterone results in a characteristic profile during anti-doping testing, which is different than the profile seen when testosterone is administered into muscle, on skin or under the tongue. Objective: The investigators aim to characterize the unique steroid doping profile following administration of intranasal testosterone to healthy, active volunteer subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAbuse of Anabolic Steroids
CountriesUnited States
CollaboratorsSports Medicine Research and Testing Laboratory, Partnership for Clean Competition

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 20, 2015
Enrollment StartNov 18, 2015
Primary CompletionJan 19, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.6 years ago

Interventions

Testosteronedrug

Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.